Member Info for havegun

CIC fund reckon Oct/Nov this year.CIC Capital and CIC Gold could run into early part of next year or maybe not.

Just had an email from Stuart,everything is looking good however there is so much detail.If anyone wants to contact him to put their mind at rest ring him on
+86 136 0113 1912

True.

We investors want is a positive listing date and nothing less.This has gone on far too long.

CIC gold twice now and they have not had the courtesy to reply.This does not do their reputation any good in my opinion.

our anniversary of our last promised listing is coming up fast.

On another board/I had some shares in Optimisa Limited that was in 2009 and they delisted too at that time,thought thats it money lost...yesterday got a letter after 9 years lol advising someone is taking them over and an offer of £13 per share...sounds good after 9 years,but won’t sell them as directors not selling because they think its worth £20-£22 per share,well if I waited 9 years with them surely this dog can’t take longer lok

wonder if we are going for the record of being the the longest stock to have been delisted before we relist[hopefully]

EICs
Equities
Investment Trusts
Pensions
Life
Offshore Funds
ETFs
VCTs
Fund Managers
News & Research
Learning
Portfolio
Tools
Passive FundsNew
0
CompanyEPIC/TIDMSEDOL/ISIN

Search for an equity factsheet
Share Tweet Print RSS
Flying Brands Ltd (FBDU)
Flying Brands Ltd
ECOG-ACRIN TO PROCESS CLINICAL TRIAL DATA USING IB
RNS Number : 8040U
Flying Brands Limited
17 July 2018

Flying Brands Limited

("Flying Brands" or the "Company")

ECOG-ACRIN TO PROCESS CLINICAL TRIAL DATA USING IMAGING BIOMETRICS SOFTWARE



IB Rad Tech will be used to assess brain tumour treatment response in multi-center trial



Imaging Biometrics®, LLC ("IB"), a wholly-owned subsidiary of Flying Brands Limited (LON:FBDU), and the American College of Radiology Imaging Network ("ACRIN") have united efforts in a multi-center Phase II trial sponsored by the Eastern Cooperative Oncology Group (ECOG)-ACRIN Cancer Research Group. The study will use IB Rad Tech™ to post-process datasets acquired from over 20 US sites to determine how well dynamic susceptibility contrast magnetic resonance imaging (DSC-MRI) works in measuring relative cerebral blood volume (rCBV) for early response to bevacizumab in patients with recurrent glioblastoma, and to ultimately correlate changes in rCBV to overall survival (OS) and progression free survival (PFS).



Patients enrolled in the study will undergo a DSC-MRI exam right before beginning treatment with bevacizumab (Genentech, San Francisco). After the baseline exam, follow-up DSC-MRI exams will be scheduled prior to the second dose administration of bevacizumab, typically 2-3 weeks after the initial dose. In total, 165 patients are estimated to participate in the study.



IB Rad Tech, a customizable software interface, acts as a "workflow wizard" to guide users through a series of automated processing steps. The specific workflow used in this study will leverage IB's FDA cleared software modules IB Neuro and IB Delta Suite to easily determine the tumor region of interest (ROI) and compute DSC-MRI-based normalized and standardized rCBV maps. Exclusive to IB, standardization is a machine-learned calibration approach that translates relative MR values to a fixed and consistent scale regardless of scanner vendor, field strength, or patient. The ability to automatically generate quantitative rCBV values consistently, independent of scanner or timepoint, makes it ideal for longitudinal assessment of treatment response.



ACRIN Principal Investigator Jerrold L. Boxerman, MD, PhD, Associate Professor of Diagnostic Imaging at The Warren Alpert Medical School of Brown University and Fellow of the American College of Radiology, said "This study will help determine if rCBV can serve as an early response imaging biomarker to an anti-angiogenic agent (bevacizumab) in patients with recurrent brain cancer. If successful, rCBV will lead the way for the incorporation of more advanced imaging biomarke

we seem to be making progress but albeit slowly.

Must be on the wrong board,I thought it was share talk not about crap which has nothing to do with the company.I shall come back on here when there are investors on here and not nutters.

What happened to I will leave you alone for now?I cannot stand people who are not invested anymore clogging up the board of genuine investors they are a pain.I personally would never do it.What a waste of time,this idiot I will put on filter.

Where are the CIC Capital audited accounts showing the significant profit?

been more than four years since we were delisted.What an absolute shambles.

the price to sell now best to ride this out.

having researched this it sure looks like James Cox is backing the RTO of Emoov.

us.

I think you are wrong trading has already finished.There will be an announcement tomorrow morning saying they are suspended.I also think we will get a RTO later this year and be well rewarded those of us who are shareholders.

Dan,just seen you giving a drilling of Simon Gorringe of Andalas.Now with all that off your chest stuff,what are you doing about sefton where I have lost a lot of money with loads of promises and we are in the gutter.Or should someone interview you

Share Tweet Print RSS Feedback PLC (FDBK) Feedback PLC Appointment of new Medical Director RNS Number : 8885P Feedback PLC 01 June 2018 1 June 2018 Feedback plc ("Feedback" or the "Company") Appointment of new Medical Director Cambridge, UK - 1 June 2018: Feedback plc ("Feedback" or the "Company") (AIM: FDBK), the specialist medical imaging technology company, announces the appointment of Professor Rory Shaw as Medical Director of Feedback's subsidiary company, Feedback Medical Limited, effective immediately. Professor Shaw is a highly experienced NHS executive with a strong track record in strategy development and international relations. In November 2013, he was appointed as Medical Director of Healthcare UK, part of the Department of International Trade, to lead the NHS International Development Team. In this role, Professor Shaw was responsible for building relationships between the NHS and foreign governments and healthcare providers in order to leverage opportunities overseas. Prior to this, Professor Shaw was a medical director in the NHS for over 15 years, latterly at North West London Hospitals Trust, and previously at Royal Berkshire Foundation Trust and Hammersmith Hospitals Trust. He has also held national roles as non-executive of the NHS Litigation Authority and previously as the first Chairman of the National Patient Safety Agency. Professor Shaw is a consultant respiratory physician and is a named author on over 140 scientific publications. David Crabb, Chief Executive Officer of Feedback plc, said: "With a unique combination of clinical and international engagement experience, Professor Shaw brings a highly complementary skill-set to the team. His clinical input, together with Dr Balaji Ganeshan's market expertise, will underpin our product development strategy following the first CE marked release of the TexRAD� technology. Furthermore, Professor Shaw's international reach will be invaluable as we continue to pursue opportunities to increase TexRAD and Cadran platform technology sales globally." Professor Rory Shaw, Medical Director of Feedback Medical Limited, commented: "The TexRAD technology provides a way of obtaining a new level of information about cancers by using Artificial Intelligence to undertake an in-depth analysis of CT scans and other images. The next exciting phase is to understand how this new information can be used in the clinical care of patients with diseases such as lung cancer, to enable better disease staging and thus to enable more effective cancer treatment." Professor Shaw will also be appointed as a Director of Feedback Medical Limited. - Ends - Notes to editors About Feedback plc Feedback plc is a specialist medical imaging technology company. It develops software and systems that provide innovative techniques and i